Yap, Christina

Adaptive designs in clinical trials: why use them, and how to run and report them

Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., et al. (2018) · BMC Medicine

Statistical Methods in Clinical TrialsStatistical Methods and Bayesian Inference

Cited by 829

Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial

Newsome, P. N., Fox, R., King, A. L., Barton, D., Than, N.-N., Moore, J., Corbett, C., Townsend, S., Thomas, J., Guo, K., et al. (2018) · The Lancet Gastroenterology & Hepatology

Liver Disease and TransplantationMesenchymal stem cell research

Cited by 162

Tolerability of bolus versus continuous gastric feeding in brain-injured patients

Rhoney, D. H., Parker, D., Formea, C. M., Yap, C., & Coplin, W. M. (2002) · Neurological Research

Clinical Nutrition and GastroenterologyEnhanced Recovery After Surgery

Cited by 105

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia

Craddock, C., Slade, D., De Santo, C., Wheat, R., Ferguson, P., Hodgkinson, A., Brock, K., Cavenagh, J., Ingram, W., Dennis, M., et al. (2019) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation

Cited by 73

The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design

Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., et al. (2020) · Trials

Statistical Methods in Clinical TrialsMeta-analysis and systematic reviews

Cited by 58

725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

Banerjee, S., Grochot, R., Shinde, R., Lima, J., Krebs, M., Rahman, R., Little, M., Tunariu, N., Curcean, A., Badham, H., et al. (2021) · Annals of Oncology

Ovarian cancer diagnosis and treatmentOvarian function and disorders

Cited by 17

Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

Krebs, M. G., Shinde, R., Rahman, R. A., Grochot, R., Little, M., King, J., Kitchin, J., Parmar, M., Turner, A., Mahmud, M., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 10

Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response

Stewart, A. R., Pickard, L., Paranjape, E., Perez, V. S., Chowdhury, S., Lustgarten, S., Coma, S., Pachter, J. A., Carey, M. S., DiMattia, G., et al. (2022) · Cancer Research

Ovarian cancer diagnosis and treatmentMelanoma and MAPK Pathways

Cited by 1